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Oral leukoplakia (OL) is the most common potentially 
malignant disorder of the oral mucosa (Neville and 
Day, 2002; Haya-Fernández et al., 2004; WHO, 2005). 
Besides oral leukoplakia, actinic cheilitis, lichen 
planus, and erythroplakia are also considered 
potentially malignant conditions affecting the oral 
cavity.  
These lesions can precede oral squamous cell 
carcinoma, which is the most common malignancy of 
the oral cavity (Neville and Day, 2002; Haya-
Fernández et al., 2004). It is believed that those 
conditions are reasonably classified as "potentially 
malignant" as it has been observed that some lesions 
evolved to malignant ones during follow-up. In 
addition, typical alterations of potentially malignant 
lesions are seen co-existing in the margins of squamo s 
cell carcinoma. Moreover, a proportion of these lesion  
show cytological, morphological, chomosomic, 
genomic, and molecular alterations that are also 




In spite of diverse and even more recently published 
definitions for oral leukoplakia, the most widely known 
is still the one proposed by World Health Organization 
(WHO) in 1978, which states that leukoplakia is a 
predominantly white patch that cannot be characterized 
clinically or histopathologically as any other definable 
lesion (Kramer et al., 1978; WHO, 2005). Oral 
leukoplakias can be classified from the clinal or 
histopathological viewpoint. Such classifications are 
discussed in detail in the topics below. 
Clinics and pathology 
Etiology 
Tobacco use is the main risk factor associated to OL 
development. OL is six times more frequent among 
smokers than non-smokers (van der Waal, 2009). The 
effects of alcohol, betel, and diet are associated s well, 
but their exact role is yet to be established (Neville and 
Day, 2002; Campisi et al., 2007; Napier and Speight, 
2008; van der Waal, 2009). A recently published 
review showed that there is not enough evidence for a 
casual association between human papilloma virus and 
OL (Feller and Lemmer, 2012). Besides, there are the 
idiopathic OL, for which no obvious aetiological factor 
can be identified. It is believed that such lesions are 
significantly more prone to develop into cancer than 
those OL with known causative factors (Napier and 
Speight, 2008). 
Epidemiology 
It is accepted that the OL prevalence varies from 1% to 
5% (Napier and Speight, 2008; van der Waal, 2009), 
with a global prevalence estimated to be 2.6% (Petti, 
2003). However, isolated reports show rates from 0.5% 
to 26.92% (Petti, 2003; Napier and Speight, 2008). 
Middle-aged and elderly man are the most affected 
individuals, and growing indexes are observed towards 
age.  
OL often arises in cheek and alveolar mucosa (Neville 
and Day, 2002). Conversely, lesions in the floor of the 
mouth and lateral border of tongue seem to present 
displastic or malignant alterations more frequently 
(Neville and Day, 2002; Napier and Speight, 2008). 
Clinics 
OL can present as homogeneous and non-homogeneous 
lesions. Homogeneous OL is a white patch slightly 
elevated, thin, white to gray, uniform, and can present 
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well defined borders or gradually mix with normal 
adjacent mucosa (Figure 1). Non-homogeneous OL can 
be nodular, verrucous, or speckled (erythroplastic) 
(Figure 2) (Warnakulasuriya et al., 2007; van der Waal, 
2009). 
The proliferative verrucous leukoplakia presents a 
multifocal evolvement, mainly in elderly female 
patients who do not present known risk factors (Figure 
3). These lesions are usually resistant to treatment and 
show a high risk for malignant transformation 
(Warnakulasuriya et al., 2007; van der Waal, 2009). 
Some alterations of the oral mucosa can mimic OL,  
and these lesions must be considered as OL differential 
diagnosis. So, for the establishment of a correct 
diagnosis of OL, such lesions must be excluded 
(Warnakulasuriya et al., 2007; van der Waal, 2009): 
1. Frictional lesion 
2. Candidiasis 
3. Linea alba 
4. Leukoedema 
5. Chemical injuries 
6. Hairy leukoplakia 
7. Nicotinic stomatitis 
Once a provisional clinical diagnosis of OL was made, 
a biopsy must be performed in order to obtain the 
histopathological features.  
This is of paramount importance because it is believ d 
that the presence and degree of epithelial dysplasia is a 
great indicator of evolution and prognosis (see below) 
(Warnakulasuriya et al., 2008). 
 
 
Figure 1: Homogeneous oral leukoplakia in the left lateral border and ventrum of the tongue. Figure 2: Non-homogeneous oral 
leukoplakia. White plaques intermixed with red patches. 
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Figure 3: Proliferative verrucous leukoplakia: multifocal involvement affecting labial mucosa, alveolar mucosa, and palate. 
 
Pathology 
Microscopically, OL can vary from hyperkeratotic 
epithelium to lesions with different degrees of 
dysplasia (WHO, 2005; Brennan et al., 2007). The term 
"dysplasia" is generally employed in the sense of a 
disordered development (Izumo, 2011).  
In a stratified squamous epithelium, architectural 
disturbances affecting normal maturation and 
stratification may occur.  
When such alterations are accompanied by cytological 
atypia, which can be detected as variations in the siz
and shape of the keratinocytes, the term "dysplasia" i  
applied (WHO, 2005; Warnakulasuriya et al., 2008).  
The frequencies of dysplastic or malignant alterations 
in OL vary from 15.6% to 39.2%, and a rate of 19.9% 
was found in a retrospective study of 3300 white 
lesions of the oral cavity (Waldron and Shafer, 1975). 
Despite many efforts towards new evaluative methods, 
the histological analysis is still the most useful method 
for grading epithelial dysplasia in OL 
(Warnakulasuriya et al., 2008).  
In this field, the WHO's system for grading epithelial 
dysplasia in OL is widely accepted among pathologists.  
However, it is not able to reflect the clinical behaviour 
of every single lesion and does not provide a clear 
therapeutic guideline to clinicians (Izumo, 2011).  
Moreover, in spite of its wide acceptance, this system 
presents great variability and low reproducibility 
(Warnakulasuriya et al., 2008; van der Waal, 2009).  
According to it, lesions are classified considering the 
architectural features and cytological alterations listed 
below (WHO, 2005). 
Architectural features: 
- Irregular epithelial stratification 
- Loss of polarity of basal cells 
- Drop-shaped rete ridges 
- Increased number of mitotic figures 
- Abnormally superficial mitoses 
- Premature keratinisation in single cells (dyskeratosis) 
Cytological alterations 
- Nuclear pleomorphism: abnormal variation in nuclear 
shape 
- Cellular pleomorphism: abnormal variation in cell 
shape 
- Anisonucleosis: abnormal variation in nuclear size 
- Anisocytosis: abnormal variation in cell size 
- Increased nuclear size 
- Increased nuclear-cytoplasm ratio 
- Atypical mitotic figures 
- Increased number and size of nucleoli 
Considering the epithelium divided into "thirds", 
lesions are classified into five categories: 
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1. Hyperplasia: increase in cell number in the spinous 
layer and/or in the basal/parabasal cell layers. There is 
regular stratification and no cellular atypia (Figure 4). 
2. Mild dysplasia: architectural disturbance only in the 
lower third of the epithelium with cytological atypia 
(Figure 5). 
3. Moderate dysplasia: architectural disturbance 
extending into the middle third of the epithelium is the 
initial criteria, but the degree of cytological atypia may 
require upgrading it to "severe" (Figure 6). 
4. Severe dysplasia: architectural disturbance affecting 
greater than two thirds of the epithelium, with 
cytological atypia (Figure 7). 
5. Carcinoma "in situ": theorically, indicates that 
malignant transformation has occurred but invasion has 
not. Full or almost full thickness architectural 
disturbance is present in viable cellular layers with 
pronounced cellular atypia. Atypical mitotic figures 
and abnormal superficial mitoses are common. 
Concerning the microscopic classification schemes for 
OL, a new binary system was proposed (Kujan et al., 
2006). Accoding to it, pathologists would observe th
same morphological criteria used in the WHO 
classification, but lesions would be classified as low-
risk OL (former "no/mild/questionable" dysplasia) or as 
high-risk OL (former "moderate/severe" dysplasia). 
Shorten the degrees of dysplasia from five, i.e. no, 
mild, moderate, and severe, to two - low-risk and high-
risk - would provide a more feasible and reproducible 
classification system. Also, it could offer a more 
reliable criteria upon which to rely for the selection of 
patient treatment. Accordingly, OL classified as "high-
risk" would be more prone to develop into cancer and, 
thus, should be removed. On the other  
hand, low-risk OL could be clinically followed up as 
they are less expected to evolve (Kujan et al., 2006; 
Warnakulasuriya et al., 2008; van der Waal, 2009). 
In a study with 218 patients with OL, the authors 
reported that high-risk OL was associated with a 4.57-
fold increased risk for malignant transformation, 
compared with low-risk OL (Liu et al., 2010). 
Moreover, in another research with 138 patients with 
histologically confirmed oral dysplasia, 115 had OL 
and 23 had lichen planus. From these 138 lesions, 37 
(26.8%) developed into cancer and the "high-risk" 
degree of dysplasia was an independent risk factor for 
transformation (Liu et al., 2011). The authors then 
suggest the utilization of high-risk dysplasia as a 
significant indicator for evaluating malignant 
transformation risk in patients with potentially 
malignant lesions. 
In a recently published paper, our research group 
showed statistically significant differences for hMLH1 
- a DNA repair protein - , p53 - a tumor supressor 
protein - , and AgNOR - an indicative of cell 
proliferation - indexes between low- and high-risk OL. 
This suggests that the biological processes linked to the 
impairment of those proteins remain enhancing from 
low-risk OL to high-risk OL.  
Thus, the use of the binary system would give support 
to a more reliable clinical approach involving the 
removal of high-risk OL (Caldeira et al., 2012). 
 
Figure 4: OL showing hyperplasia. Notice that there is regular stratification and no cellular atypia. Hyperkeratosis is present. Figure 5: 
OL showing mild dysplasia: the lower third of the epithelium shows architectural disturbance and cytological atypia. 
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Figure 6: OL with moderate dysplasia. Architectural disturbance affecting two thirds of the epithelium. Notice dyskeratosis in the granular 
layer of the epithelium (arrow). Figure 7: OL with severe dysplasia: architectural disturbance affecting greater than two thirds of the 
epithelium. Pleomorphic cells are seen in the upper third of the epithelium (arrows). Figure 8: p53 immunoexpression in OL, 200x 
magnification. (A): OL with mild dysplasia shows few immunopositive cells (arrows). (B): OL with moderate dysplasia shows an 
increased number of p53 labeled cells (arrows). Figure 9: hMLH1 immunexpression in OL, 200x magnification. (A): OL with mild 
dysplasia shows several keratinocytes labeled for hMLH1. (B): OL with severe dysplasia presents a decrease in the immunoexpression 
of hMLH1. 
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Figure 10: AgNOR staining, 1000x magnification. (A): in normal oral epithelium, keratinocytes exhibit lower AgNOR counting than in (B) 
keratinocytes in OL with severe dysplasia. 
 
Treatment 
Surgical excision, cryosurgery, laser surgery, topical or 
systemic retinoids, therapy with mouth rinses with 
attenuated adenovirus, and photodynamic therapy are 
possible therapeutics (Brennan et al., 2007; Lodi and
Porter, 2008; van der Waal, 2009). 
Evolution 
OL may persist unchanged, progress, regress, or 
disappear (Napier and Speight, 2008). The malignant 
transformation risk varies from 3.6% to 36.0%, and 
some features as presence and degree of dysplasia, 
female gender, time of duration, non-smoker patient, 
location at floor of the mouth or tongue, size higher 
than 200mm2, and non-homogeneous type, seem to be 
associated with a worse prognosis (Cruz et al., 2002; 
Holmstrup et al., 2006; Hsue et al., 2007; Smith et al., 
2009; van der Waal, 2009). Infection with human 
papilloma virus does not seem to be related to the 
progression of OL (Feller and Lemmer, 2012). 
Prognosis 
Recurrence rates are highly variable among studies, 
from 0 to 30.0% (van der Waal, 2009). 
Genetics 
Note 
Many efforts have been done to identify molecular 
markers to predict cancer development in OL. 
According to the review by Smith et al. (2009), p53, 
Ki-67, and PCNA are the most frequently investigated 
markers, but loss of heterozygosity (LOH), survivin, 
matrix metalloproteinase (MMP9), and DNA content 
are pointed as potential markers for progression of OL. 
Nevertheless, the presence and degree of epithelial 
dysplasia in OL is yet regarded as the most relevant 
indicator of progression and prognosis, influencing the 
management of the patients (Napier and Speight, 2008; 
Warnakulasuriya et al., 2008; van der Waal, 2009). 
Ki-67 is a cell cycle associated protein, of which 
expression is associated with cell proliferation. Ki-67 
immunoexpression is used as a proliferation marker in 
pathology. Kodani et al. (2001) showed that OL 
presented lower indexes of Ki-67 than oral squamous 
cell carcinoma. Also, Zhao et al. (2005) demonstrated 
that OL with mild dysplasia shows low levels of Ki-67, 
while severe dysplasia shows a significantly higher 
expression than oral normal mucosa and mild 
dysplasia. 
Our research group investigated the immunoexpression 
of hMLH1 (a protein of the mismatch repair system) in 
OL with different degrees of dysplasia. We found that 
hMLH1 indexes decreased from a lower degree of 
dysplasia to a higher one, despite statistical 
significance. So, hMLH1 immunoexpression was 
inversely related to the OL degree of dysplasia. Our
findings also suggest a role of such alterations in th s 
pathway of DNA repair as an early event in oral 
carcinogenesis (Caldeira et al., 2011a). 
Briefly, some information about the most frequent 
genetic alterations of OL are shown below. A complete 
and detailed revision on this topic was published by 
Mithani et al. (2007). 
p53 alterations: The p53 protein can induce DNA 
repair, cell cycle arrest, cell death or senescence, 
showing a pivotal role in tumor avoidance (Joerger and
Fersht, 2008). Its alteration is a common finding i 
human cancers, including those of oral mucosa 
(Kurokawa et al., 2003). Investigations demonstrated 
that the normal oral mucosa presents negative or low 
indexes of p53 immunoexpression (Kurokawa et al., 
2003; Fan et al., 2006; Caldeira et al., 2011b). 
Likewise, p53 immunopositive cells were identified in 
OL with mild dysplasia, with increasing indexes from 
hyperplasia, to dysplastic lesions (Figure 8) and to oral  
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squamous cell carcinoma, with immunopositivity found 
in superficial layers of moderate and severe dysplasias 
(Kerdpon et al., 1997; Cruz et al., 2002; Kurokawa et 
al., 2003; Caldeira et al., 2011b). The detection of p53 
in oral dysplastic lesions prompted many investigators 
to suggest that its abnormalities may constitute an arly 
event in carcinogenesis.  
Loss of heterozygosity (LOH): describes the 
elimination of a genetic loci containing tumor 
suppressor genes. In OL, LOH of the chromosome 
arms 3p and 9p seem to be related to a higher risk of 
malignant transformation. Fifty percent of OL contai s 
allelic loss of either the 3p or 9p chromosome arms 
(Mithani et al., 2007). 
Microsatellite instability (MSI) and the mammalian 
mismatch repair system (MMR): Microsatellites are 
DNA regions in which multiple repeated sequencies of 
nucleotides are found. These regions are prone to the 
occurence of mismatched DNA, developing the MSI 
phenotype (Jascur and Boland, 2006; Jiricny, 2006). 
MSI was detected in many OL and there is a trend 
toward an increased prevalence of MSI in more 
aggressive histologic OL lesions (Ha et al., 2002). The 
MMR is responsible for maintaining genomic stability 
during repeated duplication, and microsatellites regions 
are hypersensitive to MMR dysfunction. The 
immunoexpression of hMLH1 - one of the main MMR 
protein - was shown to decrease in OL with more 
severe grades of dysplasia (Figure 9) (Caldeira et l., 
2011a). Taken together, these results may suggest that 
the altered function of MMR and the occurence of MSI 
could be early events in the carcinogenic process, but 
these findings still need more investigation. 
Methylation / hypermethylation:  is an epigenetic 
alteration which can inactivate genes. In OL, it was 
described to occur in RAR-b2, p16, hMLH1, hMSH2, 
and MGMT (Ha et al., 2002; López et al., 2003; 
Youssef et al., 2004; Sengupta et al., 2007). 
AgNOR number: AgNOR staining technique is used 
to assess cellular proliferation, and normal oral 
epithelium showed lower AgNOR number than 
dysplastic OL (Figure 10), which in turn presents lower 
indexes than oral squamous cell carcinoma 
(Chattopadhyay et al., 1994; Caldeira et al., 2011b). It 
was suggested that mean AgNOR number would be 
useful in distinguishing OL with mild and moderate 
dysplasia (Chattopadhyay and Ray, 2008). 
Telomerase activity: these are the enzymes that 
degradate telomers, which are a sequence of 
nucleotides that prevents DNA to undergo degradation 
and fusion. The telomerase activity was detected in OL. 
To be noted 
Note 
In conclusion, OL is the most common potentially 
malignant oral disorder preceding oral squamous cell 
carcinoma. OL is often related to tobacco use and 
lesions may persist unchanged, enlarge, reduce or even 
disappear. Nevertheless, the presence and degree of 
epithelial dysplasia is still considered the most 
important predictor factor for malignant transformation.  
Also, it seems that the lesion duration, patient's age, 
gender, the affected site, clinical appearance, and
smoking habit are related to the risk of malignant 
transformation.  
To date, as pointed out above, no single molecular 
marker is validated as a predictor, despite several 
investigations. 
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